Central retinal artery occlusion (CRAO) is an ocular vascular occlusive disorder that causes inner retinal ischemia. Visual prognosis in patients with CRAO is poor, as 92% have permanent visual loss, with a final visual acuity (VA) of counting fingers or less, and only up to 8% of patients experience meaningful vision recovery.1-7 The stages of CRAO are as follows8,9: incomplete CRAO is characterized by diminished VA (but not complete vision loss), slight retinal edema with a slightly cherry-red spot on the macula, and delayed (but not completely interrupted) blood flow on fluorescein angiography (FA). Subtotal CRAO results in a severe reduction in VA, distinct edema of the central retina with a cherry-red spot on the macula, and a distinct delay in arterial blood flow. Total CRAO is distinguished from the aforementioned stages by massive retinal edema, without a cherry-red spot, a lack of blood flow in the perimacular arterioles, and an additional blood flow interruption of the choroid. Schmidt and Schumacher9 reported that of 46 patients with CRAO, 26 (56.5%) patients had subtotal occlusion, 10 (21.7%) had incomplete occlusion, and 10 (21.7%) had total occlusion. In another report, 21.9%, 73.0%, and 5.1% of patients were diagnosed with incomplete, subtotal, and total CRAO, respectively.8

Standard treatment modalities for CRAO include ocular massage, anterior chamber paracentesis, intraocular pressure-lowering agents (e.g., mannitol, acetazolamide, topical agents), hyperbaric oxygen, anticoagulants, and hemodilution.5,7,10-24 Thrombolysis has also been used, both intravenously and intra-arterially, for the treatment of CRAO.1,25-34 A placebo-controlled, randomized trial by Chen et al.25 showed that only 2 of 8 patients treated with an intravenous tissue-type plasminogen activator had an improvement in VA of 3 or more lines. Recently, the European Assessment Group for Lysis in the Eye (EAGLE) trial, a prospective, randomized, multicenter study,30 compared the effect of intra-arterial thrombolysis (IAT) with that of standard CRAO treatments. This trial showed that the final (1-month) visual outcomes were not different.

Keywords: central retinal artery occlusion, intra-arterial thrombolysis, outcome, reperfusion
METHODS

Inclusion and Exclusion Criteria of Subjects

**Inclusion criteria**

1. Non-arteritic CRAO
2. Symptom duration ≤24 h (or ≤7 d in cases of incomplete CRAO)
3. BCVA ≤ 20/63 (Snellen)
4. Follow-up period ≥ 1 month

**Exclusion criteria**

- Ocular factor or disease: Spontaneous improvement of vision or retinal perfusion at initial presentation (<4 h after symptom onset)
- Symptom duration of <24 hours for subtotal and total CRAO and <7 days for incomplete CRAO
- History of heart attack, intracranial hemorrhage, cerebral infarction, or intracranial surgery within 3 months
- Intracranial hemorrhage in brain MRIs at baseline
- Current antithrombotic treatment
- Intracranial hemorrhage in brain MRIs at baseline
- Previous allergy to contrast agent
- Central retinal artery occlusion from iatrogenic cause
- History of allergic reaction to contrast agent
- Unable to undergo thrombolysis due to other medical conditions

**Systemic conditions restricting thrombolysis**

1. Uncontrolled hypertension (systolic blood pressure > 200 mm Hg)
2. Coagulation disorder
3. History of heart attack, intracranial hemorrhage, cerebral infarction, or intracranial surgery within 3 months
4. Intracranial hemorrhage in brain MRIs at baseline
5. Current antithrombotic treatment
6. History of allergic reaction to contrast agent
7. Unable to undergo thrombolysis for carotid and ophthalmic artery obstruction

Between the IAT and standard treatment (ST) groups, although IAT caused higher rates of treatment-related adverse reactions. However, we believe it is unreasonable to disregard IAT as a treatment modality for all cases with CRAO based on the EAGLE trial alone. Although Schmidt and Schumacher reported different IAT efficacies for different CRAO stages, the authors overlooked the heterogeneous nature of CRAO and did not perform a detailed CRAO stage subgroup analysis. Furthermore, the primary outcome was evaluated 1 month after IAT and compared between the two treatment groups. Therefore, a comparison of the long-term procedural results could not be obtained from this randomized, prospective study. In addition, anatomic outcomes, such as central retinal artery reperfusion, were not evaluated, although central retinal artery reperfusion may be a potential benefit of the intervention.

In the present study, we compared visual and anatomic outcomes between IAT and ST in a relatively large number of patients with CRAO. Additionally, we performed CRAO stage subgroup analyses. Furthermore, we investigated factors associated with IAT treatment outcome and reviewed baseline brain magnetic resonance images (MRI) and those obtained after IAT to evaluate adverse events associated with IAT in depth.

METHODS

**Patients**

The institutional review board of Seoul National University Bundang Hospital approved this retrospective study, and the study adhered to the tenets of the Declaration of Helsinki. A review of the medical records of consecutive patients diagnosed with acute non-arteritic CRAO from January 2003 through December 2012, at Seoul National University Bundang Hospital, was performed. Patients with an initial significant visual disturbance (≤20/63 Snellen VA) and a follow-up period ≥1 month were included.

**Eligibility Criteria and Treatment**

A CRAO was diagnosed with FA and fundoscopy in all patients. Patients meeting the eligibility criteria for thrombolysis (Table 1) at initial presentation were considered for IAT. The eligibility criteria for IAT were symptom duration of <24 hours for subtotal and total CRAO and <7 days for incomplete CRAO. Systemic conditions restricting thrombolysis, including uncontrolled hypertension, coagulation disorders, and antithrombotic treatments, excluded patients from receiving IAT. Cases with combined ocular pathologies that might influence visual outcome or other ocular ischemic disease, such as ocular ischemic syndrome, central retinal vein occlusion, and proliferative diabetic retinopathy, were also excluded. Iatrogenic cases of CRAO were also excluded.

The ST group included patients who were eligible for IAT but refused the treatment and those who met the eligibility criteria for IAT but visited the hospital before IAT initiation at our hospital in May 2008. Those patients were treated with ocular massage (repeated manual compression for 10–15 seconds followed by sudden release, using a 3-mirror contact lens for 3–5 minutes) and IOP-lowering agents (topical timolol 0.5%, oral acetazolamide 500 mg).

After an ophthalmologist provided a detailed procedure description and discussed potential complications, IAT was performed, along with cerebral angiography using a biplane angiographic unit (IntegrisAllura; Philips Medical Systems, Eindhoven, The Netherlands). The microcatheter (Excelsior SL-10; Stryker Neurovascular, Fremont, CA) was placed in the proximal segment of the ophthalmic artery, and up to 500,000 units of urokinase (Green Cross, Yongin, Korea) was slowly injected by hand. During the IAT procedure, an ophthalmologist checked VA and performed fundoscopic examination to evaluate retinal changes following each 100,000-unit injection of urokinase until visual improvement was noticed. If visual improvement was not noted, up to 500,000 units of the thrombolytic was infused, provided the patient had no bleeding risk.

**Examinations**

We obtained data pertaining to age, sex, and time from symptom onset to treatment. All measurements of best-corrected VA (BCVA) were obtained using a standardized Snellen chart. Snellen VA measurements were converted into logarithmic minimum angle of resolution (logMAR) equivalent values for statistical analysis. The numerical scores for profound low vision, namely, counting fingers or worse, were substituted for logMAR values, as suggested by Lange et al.

The amounts of visual improvement at 1 month and at the final visit were calculated by the change in BCVA from baseline. A clinically significant visual improvement was defined as a visual improvement ≥ 0.3 logMAR.

To quantify the degree of circulatory disturbance in each case of CRAO, the arm-to-retina time until fluorescein appearance and arteriovenous passage time were evaluated for pre-treatment FA images, obtained at the time of CRAO diagnosis. The central retinal artery was considered reperfused if follow-up FA images showed significantly reduced arm-to-retina time and arteriovenous passage time. Early reperfusion was assessed using FA images obtained...
within 3 days of treatment, and final reperfusion was evaluated 1 month after treatment.

In both the IAT and ST groups, adverse reactions were identified by clinical examinations and from patient symptoms. Sixty-five patients, including 35 in the IAT group and 30 in the ST group, underwent brain MRI at baseline. Thirty-one patients in the IAT group underwent brain MRI after IAT. In 25 patients from the IAT group, diffusion-weighted MRI images obtained before and after IAT were compared to detect new ischemic lesions following IAT. Hemorrhagic or ischemic lesions were confirmed by the consensus from one trained neuroradiologist and one trained neurologist.

Statistical Analyses

We compared final visual and anatomic outcomes (reperfusion status) of the IAT with those of the ST group. After categorizing CRAO as incomplete, subtotal, and total, as suggested by Schmidt et al., we analyzed treatment outcomes between the IAT and ST groups. For comparison, the Mann-Whitney U test or Student’s t-test was used, depending on normality (determined by the Shapiro-Wilk test), to compare means of continuous variables. Dichotomous data were analyzed using the $\chi^2$ test or Fisher exact test.

We also investigated predictive factors for visual outcome. Multiple regression analyses were performed to identify factors associated with 1-month or final BCVA by using clinical parameters. Descriptive statistics were performed with baseline cerebral pathologies and adverse reactions following IAT. Commercial software was used for all statistical analyses (SPSS version 17.0; SPSS, Inc., Chicago, IL for Windows; Microsoft, Redmond, WA). Statistical significance was assigned at a $P$ value of $<0.05$.

RESULTS

Clinical Characteristics of Included Patients

Of 127 consecutive acute nonarteritic CRAO patients evaluated during the study period, 101 (26 [26%] incomplete, 48 [48%] subtotal, 27 [27%] total) CRAO patients met inclusion criteria (Fig. 1). The IAT and ST groups included 57 (13 incomplete, 28 subtotal, 16 total) and 44 (13 incomplete, 20 subtotal, and 11 total) CRAO patients, respectively. The ST group included 33 patients who refused IAT because of safety concerns and 11 patients who visited our hospital before May 2008, the time IAT became available to our acute CRAO patients. All 11 patients were treated with ocular massage and IOP-lowering agents. Representative cases with CRAO are shown in Figure 2. Significant differences in demographic data between IAT ($n=57$) and ST ($n=44$) groups were not found (Table 2), except for time between symptom onset and treatment in the subtotal (16.4 ± 11.2 hours in the IAT group versus 40.5 ± 30.3 hours in the ST group) and total CRAO subgroups (11.2 ± 6.4 hours in the IAT group versus 33.0 ± 25.5 hours in the ST group).

Visual Outcome

The mean BCVA values at the initial visit, 1 month after treatment, and final visit are shown in Figure 3. Overall, initial, 1-month, and final BCVAs were not significantly different between the two groups. However, subgroup analyses among those with incomplete CRAO revealed significant differences in final BCVA between the
groups (1.57 ± 0.73 in the ST group versus 0.83 ± 0.61 in the IAT group, \( P = 0.020 \)).

Among all patients, the amounts of visual improvement between 1 month (0.13 ± 0.46 [IAT group] vs. 0.05 ± 0.44 logMAR [ST group], \( P = 0.519 \)) and at the final visit (0.31 ± 0.63 vs. 0.08 ± 0.51, \( P = 0.062 \)) were not significantly different between the IAT and ST groups. There were no significant differences in visual improvement at 1 month or the final visit between the two groups in subgroup comparisons among patients with subtotal or total CRAO (Table 4). However, statistically significant differences were noted in the comparisons between groups of visual improvement at 1-month and at the final visit among patients with incomplete CRAO (both, \( P < 0.001 \)).

The percentages of eyes with a BCVA equal to or better than 20/200 and those with a clinically significant visual improvement (\( \geq 0.3 \text{logMAR} \)) in the IAT and ST groups are presented in Figures 4A and 4B, respectively. Among all included patients, percentages were not significantly different between the two groups at 1 month after treatment (\( P = 0.108 \) and 0.639, respectively). However, at the final visit, the percentage of eyes with a BCVA equal to or better than 20/200 was significantly higher in the IAT group (\( P = 0.001 \)).

Table 2. Comparison Between Demographic and Clinical Characteristics of the IAT and ST Groups

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>IAT Group</th>
<th>ST Group</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>57</td>
<td>44</td>
<td>NA</td>
</tr>
<tr>
<td>Mean age, y (range)</td>
<td>58.3 ± 14.7 (18–79)</td>
<td>64.5 ± 17.4 (19–90)</td>
<td>0.054</td>
</tr>
<tr>
<td>Male:female</td>
<td>36:21</td>
<td>29:15</td>
<td>0.775</td>
</tr>
<tr>
<td>Time from symptom onset to treatment, hours (range)</td>
<td>22.7 ± 30.6 (1–172)</td>
<td>35.9 ± 27.6 (2–120)</td>
<td>0.054</td>
</tr>
<tr>
<td>Incomplete CRAO, ( n = 26 )</td>
<td>50.5 ± 54.3 (9–172)</td>
<td>29.7 ± 26.8 (4–34)</td>
<td>0.391</td>
</tr>
<tr>
<td>Subtotal CRAO, ( n = 48 )</td>
<td>16.4 ± 11.2 (3–42)</td>
<td>40.5 ± 30.3 (2–120)</td>
<td>0.011</td>
</tr>
<tr>
<td>Total CRAO, ( n = 27 )</td>
<td>11.2 ± 6.4 (1–23)</td>
<td>33.0 ± 25.5 (5–72)</td>
<td>0.034</td>
</tr>
<tr>
<td>Mean follow-up period, mo (range)</td>
<td>9.9 ± 12.4 (1–55)</td>
<td>13.3 ± 19.2 (1–74)</td>
<td>0.308</td>
</tr>
<tr>
<td>Mean initial visual acuity, logMAR (range)</td>
<td>2.23 ± 0.47 (0.52–2.9)</td>
<td>2.01 ± 0.66 (0.22–2.9)</td>
<td>0.065</td>
</tr>
<tr>
<td>Stage, incomplete:subtotal:total</td>
<td>13:28:16</td>
<td>13:20:11</td>
<td>0.742</td>
</tr>
</tbody>
</table>

NA, not applicable.

* \( P \) values in boldface indicate statistical significance.
greater in the IAT group than in the ST group (19.3% vs. 4.5%, respectively, \( P = 0.026 \)), whereas the percentages of eyes with clinically significant visual improvement were not significantly different between the two groups (42.1% vs. 25%, respectively, \( P = 0.056 \)). The percentages of eyes with a BCVA equal to or better than 20/200 and that had a clinically significant visual improvement at the final visit were significantly greater in eyes with incomplete CRAO treated with IAT than in ST eyes (\( P = 0.008 \) and 0.002, respectively). In contrast, the same comparisons among the patients with subtotal or total CRAO revealed no significant intergroup differences at 1 month or at the final visit.

### Anatomic Outcome

The early reperfusion rate, as evaluated by FA, was significantly greater in the IAT group than in the ST group (40 of 54 [74.1%] vs. 12 of 28 [42.9%], respectively, \( P = 0.005 \)), whereas the final reperfusion rate was not significantly different (45 of 51 [88.2%] vs. 25 of 31 [80.6%], respectively, \( P = 0.354 \)).

### Table 3. Comparison Between Overall Anatomic and Visual Outcomes of the IAT and ST Groups

<table>
<thead>
<tr>
<th>Outcome</th>
<th>IAT Group, ( n = 57 )</th>
<th>ST Group, ( n = 44 )</th>
<th>( P )†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean amount of visual improvement at 1 mo, logMAR</td>
<td>0.13 ± 0.46</td>
<td>0.05 ± 0.44</td>
<td>0.519</td>
</tr>
<tr>
<td>Mean amount of visual improvement at the final visit, logMAR</td>
<td>0.31 ± 0.63</td>
<td>0.08 ± 0.51</td>
<td>0.062</td>
</tr>
<tr>
<td>No. of eyes with BCVA ≥20/200 at 1 mo, %</td>
<td>6, 10.5</td>
<td>1, 2.3</td>
<td>0.108</td>
</tr>
<tr>
<td>No. of eyes with BCVA ≥20/200 at the final visit, %</td>
<td>11, 19.3</td>
<td>2, 4.5</td>
<td>0.026</td>
</tr>
<tr>
<td>No. of eyes showing clinically significant visual improvement at 1 mo, %*</td>
<td>18, 31.6</td>
<td>12, 27.3</td>
<td>0.689</td>
</tr>
<tr>
<td>No. of eyes showing clinically significant visual improvement* at the final visit, %</td>
<td>24, 42.1</td>
<td>11, 25</td>
<td>0.056</td>
</tr>
</tbody>
</table>

Anatomic outcome

<table>
<thead>
<tr>
<th>Outcome</th>
<th>IAT Group, ( n = 57 )</th>
<th>ST Group, ( n = 44 )</th>
<th>( P )†</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of eyes showing early (≤3 d) reperfusion/no. of FA performed, %</td>
<td>40/54, 74.1</td>
<td>12/28, 42.9</td>
<td>0.005</td>
</tr>
<tr>
<td>No. of eyes showing final (1 mo) reperfusion/no. of FA performed, %</td>
<td>45/51, 88.2</td>
<td>25/31, 80.6</td>
<td>0.346</td>
</tr>
</tbody>
</table>

* Visual improvement ≥ 0.3 logMAR.
† \( P \) values in boldface indicate statistical significance.
<table>
<thead>
<tr>
<th>Demographic Data</th>
<th>Incomplete CRAO, N = 26</th>
<th>Subtotal CRAO, N = 48</th>
<th>Total CRAO, N = 27</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean age</strong></td>
<td>60.5 ± 10.8</td>
<td>56.4 ± 17.4</td>
<td>59.9 ± 12.7</td>
</tr>
<tr>
<td><strong>Mean time from symptom onset to treatment, h</strong></td>
<td>50.5 ± 54.3 (9–172)</td>
<td>16.4 ± 11.2 (3–42)</td>
<td>11.2 ± 6.4 (1–23)</td>
</tr>
<tr>
<td><strong>Mean initial BCVA, logMAR (range)</strong></td>
<td>1.93 ± 0.56 (20–60-HM)</td>
<td>2.45 ± 0.37 (20–150-NLP)</td>
<td>2.60 ± 0.29 (HM-NLP)</td>
</tr>
<tr>
<td><strong>Visual outcome</strong></td>
<td>Mean visual improvement at 1 month, logMAR (range)</td>
<td>1.08 ± 0.21 (0.40–1.9)</td>
<td>0.08 ± 0.57 (–1.3–1.3)</td>
</tr>
<tr>
<td></td>
<td>Mean visual improvement at final visit, logMAR (range)</td>
<td>1.08 ± 0.53 (0–1.6)</td>
<td>1.08 ± 0.53 (0–1.6)</td>
</tr>
<tr>
<td></td>
<td>No. of eyes with 1-mo BCVA ≥20/200 (%)</td>
<td>6 (46.2)</td>
<td>6 (46.2)</td>
</tr>
<tr>
<td></td>
<td>No. of eyes with final BCVA ≥20/200 (%)</td>
<td>9 (69.2)</td>
<td>2 (15.4)</td>
</tr>
<tr>
<td></td>
<td>No. of eyes with clinically significant visual improvement at 1-month (%)‡</td>
<td>10 (76.9)</td>
<td>5 (46.2)</td>
</tr>
<tr>
<td></td>
<td>No. of eyes with clinically significant visual improvement at final visit (%)‡</td>
<td>11 (84.6)</td>
<td>5 (25.1)</td>
</tr>
<tr>
<td><strong>Anatomic outcome</strong></td>
<td>No. of early (&lt;3d) reperfusion/no. of FA performed</td>
<td>11/11 (100)</td>
<td>5/9 (55.6)</td>
</tr>
<tr>
<td></td>
<td>No. of final (1-mo) reperfusion/no. of FA performed</td>
<td>11/11 (100)</td>
<td>5/8 (62.5)</td>
</tr>
</tbody>
</table>

FA, fluorescein angiography; HM, hand motion; NA, not applicable; NLP, no light perception.

* P values were obtained using the Fisher exact test for dichotomous variables and Mann-Whitney U test for continuous variables.
† P values were obtained using the χ² test for dichotomous variables and Student's t-test for continuous variables.
‡ Visual improvement ≥ 0.3 logMAR.
P = 0.346). Subgroup analyses revealed significant differences in early reperfusion rates between the IAT and ST groups with incomplete CRAO (100% vs. 55.6%, P = 0.026), as presented in Table 4.

**Table 5.** Neurological and Non-Neurological Adverse Reactions after Intra-Arterial Thrombolysis in Patients With Central Retinal Artery Occlusion

<table>
<thead>
<tr>
<th>Reaction</th>
<th>No. of Patients/No. of MRIs or Examinations Performed, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurological adverse reactions after IAT</td>
<td></td>
</tr>
<tr>
<td>Embolic infarction*</td>
<td>8/31, 25.8</td>
</tr>
<tr>
<td>Symptomatic neurological deterioration†</td>
<td>1/57, 1.8</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>0/31</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>0/31</td>
</tr>
<tr>
<td>Death related to any neurologic problem</td>
<td>0/57</td>
</tr>
<tr>
<td>Non-neurological non-ocular adverse reactions after IAT</td>
<td></td>
</tr>
<tr>
<td>Hematoma at vessel puncture sites</td>
<td>2/57, 3.5</td>
</tr>
<tr>
<td>Headache</td>
<td>1/57, 1.8</td>
</tr>
<tr>
<td>Tinnitus</td>
<td>1/57, 1.8</td>
</tr>
<tr>
<td>Hyperesthesia</td>
<td>1/57, 1.8</td>
</tr>
<tr>
<td>Treatment-associated infection</td>
<td>0</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>0</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>0</td>
</tr>
<tr>
<td>Ocular adverse reactions after IAT</td>
<td></td>
</tr>
<tr>
<td>Increased intraocular pressure</td>
<td>2/57, 3.5</td>
</tr>
</tbody>
</table>

* Asymptomatic in 7 patients, symptomatic in 1 patient.
† Hemianopsia which resolved completely in 7 days.

**Factors Associated With Visual Outcome**

Among the clinical factors examined (e.g., age, sex, CRAO stage, CRAO treatment, initial BCVA, time between symptom and treatment, follow-up period, arm-to-retina time, and arteriovenous passage time), CRAO stage was the only factor significantly associated with 1-month BCVA (P < 0.001, multiple regression analysis). Initial BCVA (P = 0.038) and CRAO stage (P < 0.001) were significantly associated with final BCVA.

**Adverse Reactions**

Table 5 shows the neurological and non-neurological adverse reactions associated with IAT, as identified by clinical and laboratory examinations and brain MRI. After IAT, we observed cases of hematoma at the vessel puncture site (n = 2 [3.5%]), increased IOP (n = 2 [3.5%]), hemianopsia (n = 1 [1.8%]), headache (n = 1 [1.8%]), tinnitus (n = 1 [1.8%]), and hyperesthesia (n = 1 [1.8%]) in the IAT group (Table 5).

Brain MRI provided detailed information regarding baseline cerebral pathology and adverse reactions following IAT. Eight of 65 (12.3%) patients with CRAO had concurrent acute or old ischemic lesions, which were detected in baseline MRI images. In the IAT group, post-IAT MRI images showed that 8 of 31 (25.8%) patients had acute infarctions. Diffusion-weighted images identified new ischemic lesions, occurring after IAT in 2 of 25 (8%) patients in the IAT group. Among 8 patients showing acute infarctions on post-IAT brain MRI, 7 cases were asymptomatic and clinically insignificant. Neurologic examinations did not reveal any sign suggestive of cerebral infarct, and the infarcted lesions in MR images were small. However, 1 patient exhibited hemianopsia due to right occipital lobe infarct with posterotemporal branch occlusion of the right middle cerebral artery, followed by immediate mechanical thrombolysis for recanalization, that completely recovered.
within 7 days. No case presented with intracranial hemorrhage or transient ischemic attack following IAT.

After a thorough stroke risk factor workup, including assessment of potential cardioembolic stroke sources, we treated the patient with embolic infarction following IAT with an antiplatelet agent and a cholesterol-lowering medication (statin) for the secondary prevention of stroke. Post-IAT headache resolved after oral non-steroidal anti-inflammatory drug therapy within 1 or 2 days, and both tinnitus and hyperesthesia lasted only for a few hours and resolved without treatment. Hematomas occurring at the vessel puncture site were not large in our patients, and hemostasis was obtained with bed rest and by applying manual compression for 10 to 20 minutes. Increased intracranial pressure caused by neovascular glaucoma required topical IOP-lowering medications and, eventually, valve implant surgery for uncontrolled IOP.

**Discussion**

This study suggests that IAT may be beneficial for visual recovery in eyes with incomplete CRAO. Although retinal artery reperfusion occurred more frequently in the IAT group among patients with CRAO, patients with subtotal or total CRAO in the IAT group showed visual improvement comparable to those in the ST group. Although the randomized EAGLE trial did not show that IAT was superior to ST, our results suggest that IAT may be beneficial for visual recovery in select cases of CRAO and that it may be a viable treatment option for these cases. However, in 8% of patients, IAT resulted in a new cerebral infarct that was clinically insignificant but was detected by comparing brain MRI images obtained before and after IAT. Therefore, the risk of an associated infarct following IAT should be carefully considered when deciding to perform the treatment.

Previously, studies by Schmidt et al.\(^8\) and Schmidt and Schumacher\(^9\) suggested dividing the three CRAO stages on the basis of clinical, fundoscopic, and angiographic findings. Their reported subgroup percentages were comparable to ours (26%, 48%, and 27% for incomplete, subtotal, and total CRAO, respectively). Schmidt and Schumacher\(^9\) reported different IAT efficacies according to the stage of CRAO. They suggested that IAT has a beneficial effect in patients with incomplete CRAO. However, their study did not include a control group, which is essential for providing evidence for IAT use in CRAO. By comparing both functional and anatomical outcomes between the IAT and ST groups in patients with CRAO, our study showed that early reperfusion rates were significantly greater in the IAT group than in the ST group, indicating that IAT has a beneficial effect on reperfusion. The anatomic outcomes might be associated with visual outcome, as the temporal changes in BCVA showed different patterns from 1 month after treatment to the final visit between the IAT and ST groups (further improved and deteriorated BCVA, respectively).

The clinical efficacy of IAT for CRAO has been reported in several retrospective studies and meta-analyses.\(^{26-29,31,32,34}\) However, the treatment outcomes vary greatly from study to study. Our findings, with regard to visual outcomes, differed from those reported in the EAGLE study. More specifically, the BCVA changes at 1 month in the IAT and ST groups in the EAGLE study (0.45 and 0.44 logMAR, respectively) differed from those in our study (0.13 and 0.05 logMAR, respectively). The discrepancies in the types of treatment performed for the ST group (6 modalities in the EAGLE trial versus 3 modalities in our study), the time from onset to treatment (longer in our study), and materials used for thrombolysis may have resulted in the discrepancy between BCVA changes in previous studies and ours. However, the EAGLE study and our study in common showed that overall visual outcomes in the IAT and ST groups were similar. Our study also suggests that IAT may be beneficial when used for treating incomplete CRAO.

Retinal survival time after CRAO was reported to be as long as 97 to 100 minutes, with irreversible retinal damage occurring beyond 105 minutes in experimental models.\(^{38}\) However, the extreme retinal clamping used in those experimental settings does not reflect the actual clinical conditions under which CRAO is treated in humans. For incomplete CRAO, the retinal tolerance time may be prolonged and retinal ischemic injury can be reversible after retinal reperfusion by IAT. For instance, 84.6% of patients with incomplete CRAO in the IAT group showed a clinically significant visual improvement at the final visit, whereas only 14.3% of patients with subtotal CRAO and none with total CRAO had a clinically significant visual improvement after IAT. However, if patients with incomplete CRAO are not treated by IAT and early reperfusion is not obtained, as was the case in the ST group, retinal ischemic injury may lead to permanent vision loss even if reperfusion is spontaneously obtained without invasive procedures in more delayed fashion than in the IAT group. To support this hypothesis, the retinal tolerance time in incomplete CRAO should be investigated in future studies. Regarding the tolerance time, 1 patient with incomplete CRAO showed a clinically significant visual improvement after IAT, which was performed 172 hours after initial symptom onset. On the basis of this finding, our eligibility criterion for IAT was set at an interval of ≤7 days from symptom onset to treatment in cases of incomplete CRAO.

The major complication related to IAT was cerebral infarct, and minor complications included headache, dizziness, and increased IOP. The EAGLE study reported IAT-related major complications (cerebral and cerebellar hemorrhage) in 2 of 44 patients (4.5%). One of the main reasons for the early termination of the EAGLE trial was the higher rate of complications in the IAT group, including 2 cases with cerebral or cerebellar hemorrhage. The main safety concern after thrombolytic therapy is hemorrhagic transformation of the infarct.\(^{39}\) Therefore, with regard to evaluating the safety of IAT, baseline brain imaging, which was not obtained in the EAGLE trial or in the study by Chen et al.,\(^{25}\) would be valuable for detecting cerebral infarct before thrombolysis and for assessing the risk of hemorrhage and infarction associated with IAT.\(^{40}\) In our study, brain MRI data showed that a non-negligible proportion of patients (12.3%) had baseline acute and old ischemic lesions, but no IAT case presented with hemorrhagic transformation. The incidence of embolic infarction after IAT (25.8%) was comparable with that of silent embolic events (23%) following diagnostic angiography and intervention,\(^{41}\) indicating that IAT for CRAO did not carry an increased risk in comparison to conventional diagnostic and interventional angiography. However, silent infarction can be a precursor of symptomatic stroke and is also associated with progressive brain damage and vascular dementia.\(^{42}\) These adverse neurologic reactions should be carefully considered in the context of clinical decision making.

Our study has several limitations. The retrospective nature of the study introduces inherent possibilities of bias, especially selection bias, because it is difficult to control bias and confounders in retrospective studies. In particular, the time between CRAO onset and treatment could not be controlled in this study. Although not statistically significant, the time from onset to treatment tended to be longer in the ST group, which may have affected our results. However, our main finding of a significant difference in visual outcome between the IAT and ST groups in incomplete CRAO may not have resulted from the longer period between CRAO onset and treatment in the ST group. Among the patients with incomplete CRAO, the period...
In conclusion, IAT may have the advantage of early retinal reperfusion in eyes with acute CRAO and significant efficacy in visual restoration in those with incomplete CRAO. However, the adverse events revealed by clinical examinations and brain MRI indicate that IAT should be performed cautiously and selectively.

Acknowledgments

Supported by a grant from the National Research Foundation of Korea (Grant 2012R1A2A2A02012821). The authors alone are responsible for the content and writing of the paper.

Disclosure: S.J. Ahn, None; J.M. Kim, None; J.-H. Hong, None; S.J. Woo, None; J. Ahn, None; K.H. Park, None; M.-K. Han, None; C. Jung, None

References


Intra-Arterial Thrombolysis in Central Retinal Artery Occlusion

IOVS | November 2013 | Vol. 54 | No. 12 | 7755


